Search results: (10000)
News How to Secure Diabetics with Atrial Fibrillation During PCI?
Optimal management of patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) continues to be the subject of studies. A sub-analysis of the RE-DUAL study focused on this issue in a high-risk group of patients with diabetes.
News Physiotherapy as Part of Comprehensive Care for People with Hemophilia – Recommendations vs. Reality
It appears that the physiotherapeutic care provided in reality to people with hemophilia does not align with current recommendations, which see it as an integral part of a multidisciplinary approach. Therefore, in the summer of 2020, an initiative of experts from various countries, including the Czech Republic, was formed to address this issue.
News Are there mutual interactions between candesartan and amlodipine in the combination therapy of hypertension?
Monotherapy is often insufficient in the treatment of hypertension; however, combining antihypertensives with different mechanisms of action can be complicated by their mutual interactions. Therefore, a study by South Korean authors examined the pharmacokinetic interactions between candesartan and amlodipine, substances that are commonly used together in combined treatment.
News Undiagnosed Hereditary Angioedema in Pregnancy – Case Study
Delayed diagnosis or misdiagnosis is not uncommon with hereditary angioedema (HAE), especially during pregnancy and the postpartum period. A case study by Canadian authors illustrates that HAE should be considered in the differential diagnosis for any patient with unexplained abdominal pain and recurrent swellings without the presence of urticaria.
News Polatuzumab Vedotin in the Treatment of NHL - News from the 25th EHA Congress
Polatuzumab vedotin (Polivy) is approved in the EU for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), for whom hematopoietic stem cell transplantation (HSCT) is not suitable. We provide an overview of the latest news regarding the role of this modern medicine in the therapy of non-Hodgkin's lymphomas (NHL), presented at the 25th Congress of the European Hematology Association (EHA), held virtually due to the pandemic situation.
News Comparison of the Risk of Interstitial Lung Disease in Patients with RA with Biological and Targeted Disease-Modifying Antirheumatic Therapy
The authors of a newly published study sought to answer whether the risk of developing interstitial lung disease in patients with rheumatoid arthritis (RA) is affected by the administration of biological or targeted disease-modifying antirheumatic therapy. They analyzed data from more than 28,000 patients with RA.
News Fixed Combination of Tiotropium/Olodaterol in SMI Inhaler and Its Benefits in COPD Treatment
The TRONARTO study, whose conclusions were published in the International Journal of Chronic Obstructive Pulmonary Disease, addressed the issue of inhalation therapy in patients with chronic obstructive pulmonary disease (COPD). The authors focused on the effect of the combination of tiotropium and olodaterol in an SMI (soft mist inhaler) type inhaler.
News Finger on the Pulse of the Times with Automated Peritoneal Dialysis and Remote Patient Monitoring
The method of peritoneal dialysis brings many advantages to patients with chronic kidney disease and significantly eases their lives. Peritoneal dialysis saves time for both the patients themselves and the attending healthcare personnel. Modern medicine now offers an innovative tool that can remotely monitor the patient's condition, with the possibility of adjusting the treatment regimen.
News Addition of ixazomib to lenalidomide and dexamethasone in multiple myeloma − Data from real-world Czech practice
A group of Czech and Slovak experts led by Associate Professor Jiří Minařík from the Hemato-Oncology Clinic of the Faculty of Medicine UP and University Hospital Olomouc published the final results of an observational study evaluating the addition of ixazomib to the combination with lenalidomide and dexamethasone in patients with relapsing/refractory multiple myeloma (RRMM). This involves experiences from real clinical practice, with data obtained from the Czech Registry of Monoclonal Gammopathies.
News Good news for sleep in patients with axial spondyloarthritis – ixekizumab effectively reduces night-time back pain
The targeted treatment of axial spondyloarthritis currently relies on the anti-inflammatory effects of tumor necrosis factor (TNF) inhibitors, interleukin IL-17 inhibitors, and Janus kinase (JAK) inhibitors. Besides the objective efficacy of these targeted treatments, it is crucial to describe their influence on subjective symptoms for decision-making in clinical practice. The evaluation of the analgesic effect of ixekizumab (IXE) was provided by the randomized controlled trial COAST-V.
News Prevalence and Clinical Impact of Overweight and Obesity in the Hemophilia Population
Obesity is classified as a lifestyle disease with increasing prevalence and a rising contribution to morbidity and mortality in the general population. The epidemic of overweight and obesity also does not spare individuals with hemophilia. According to epidemiological data, the prevalence of obesity is also increasing in this population, causing a number of complications in many health aspects.
News Third Generation Targeted Therapy for ROS1-Positive NSCLC
The potent third-generation tyrosine kinase inhibitor, lorlatinib, has shown activity in preclinical studies against nearly all known mutations in the ALK and ROS1 genes that lead to resistance to crizotinib treatment. Moreover, lorlatinib crosses the blood-brain barrier, offering hope for patients with CNS metastases. The results of a clinical evaluation of the efficacy and safety of lorlatinib in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) were published in The Lancet Oncology.
News How do patients perceive the change in appearance of chronically used medications and to what extent does it lead to non-adherence to therapy?
Doctors regularly encounter patients in their offices who complain about changes in the appearance of their chronically used medications. Such a change can even be the cause of non-adherence to treatment. Interesting findings on this topic were brought by an American survey aimed at identifying the preferences, experiences, and reactions of patients and pharmacists related to changes in the appearance of medications.
News Overlap of SGLT2 Inhibitors from Diabetology to Cardiology
As recent research shows, one of the modern groups of antidiabetic drugs - SGLT2 inhibitors, also known as gliflozins - brings benefits not only in diabetology but also in cardiology and nephrology. It has been confirmed that representatives of this class of drugs prolong patients' lives, reduce the incidence of major cardiovascular (CV) events and the risk of heart failure (HF), and improve renal function. A recently published study additionally indicates that the CV benefit of empagliflozin is independent of the number of compensated CV risk factors and manifests within the first 3 months of treatment.
News Is it safe to start dabigatran in the first days after ischemic stroke?
For patients after cardioembolic ischemic stroke (iCMP), starting anticoagulant therapy is crucial, but it is not strictly defined how many days after iCMP it is ideal to begin. The article provides a summary of a recent observational study that investigated the appropriate timing of starting dabigatran in patients with non-valvular atrial fibrillation (NVAF) after their first iCMP who were treated with intravenous thrombolysis or endovascular thrombectomy.
News Alemtuzumab – Does Age Matter? Or Not?
The authors of a study published this year focused on the safety and efficacy of alemtuzumab in patients with relapsing-remitting multiple sclerosis (RRMS). How did it perform over the observed period in patients of different age categories?
News Subcutaneous pdC1-INH in Patients with Hereditary Angioedema in Real-World Practice
Italian authors published a series of cases of patients with hereditary angioedema caused by C1 inhibitor deficiency (C1-INH-HAE) with long-term prophylaxis using human plasma-derived C1 inhibitor concentrate (pdC1-INH) in subcutaneous form. They supplement the results of the placebo-controlled COMPACT study, in which s.c. pdC1-INH reduced the frequency of attacks, with insights from real-world practice in 5 patients treated at the angioedema therapy center in Milan, Italy.
News CASE STUDY: Surgical Procedure in an Adolescent Patient with Severe Hemophilia A on Emicizumab Prophylaxis
This case study is narrated by MUDr. Bohumír Blažek from the Clinic of Pediatric Medicine at LF OU and FN Ostrava. The patient is a 17-year-old boy with severe hemophilia A. Several months prior to the procedure under discussion, he was switched from prophylactic factor VIII administration to emicizumab prophylaxis. Subsequently, an extraction of all four molars was planned for orthodontic reasons. The case study describes the hematologist's approach to the procedure and the subsequent healing process.
News Interactive Case Study: AATD – Alpha-1-Antitrypsin Deficiency
We present a case study of a man who was 41 years old at the time of his first contact with a pulmonary doctor. He came with symptoms of allergic seasonal rhinoconjunctivitis, proven sensitivity to spring trees, grasses, and dust mites, otherwise healthy, a parrot breeder. He is a former smoker with a smoking history of 20 pack-years. He was examined for exertional dyspnea, cough, recurrent respiratory infections, and wheezing. Try to follow the further diagnostic procedure and considerations with us, where you can choose between different options. At the same time, you will verify whether you proceeded correctly, along with the justification for the step taken.
News Virtual Echocardiography as a Potential Screening Tool for the Diagnosis of Primary Pulmonary Hypertension
Primary pulmonary hypertension disease is associated with a poor prognosis. Early diagnosis and the implementation of specific therapy are necessary to improve patients' prospects. In the near future, virtual echocardiography, which has shown good results in published studies, may become a valuable screening tool.
News Positive Effect of Diosmin on Venous Disease in Terms of Factors Responsible for Angiogenesis
A study published last year monitored the impact of diosmin on laboratory and clinical parameters related to the pathophysiology of chronic venous disease in patients.
News fSCIG in Elderly Patients with PID or SID in Real Clinical Practice
The work of a team of German and Dutch authors presents data on the real clinical use of 10% subcutaneous immunoglobulin facilitated by hyaluronidase (fSCIG) in elderly patients with primary (PID) or secondary (SID) immunodeficiency.
News Brentuximab Vedotin and Relapsing/Refractory NHL with High Expression of CD30
A recently published study by authors from South Korea focused on examining the efficacy of brentuximab vedotin in patients with non-Hodgkin lymphomas (NHL) that highly express CD30 (i.e., > 30% CD30-positive tumor cells based on immunohistochemistry), where the disease had relapsed or was refractory to previous treatments.
News Management of Musculoskeletal Issues in Hemophiliacs at a Glance
Musculoskeletal issues are among the most common complications of hemophilia. Prevention and early treatment are crucial, and this message is also addressed to specialists by the World Federation of Hemophilia (WFH) guidelines from 2020.